AURKA and myeloproliferative neoplasm: Similarly, Wen et al. reported that AURKA is upregulated in primary cells from MPN patients and that the genetic or pharmacological inhibition of AURKA reduces bone marrow fibrosis in JAK2V617F- and MPLW515L-driven models23.